DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) Return on assets

Alert me on Return on assets

DexCom, Inc.'s return on assets over the twelve months to 30 June 2026 was 14.5%, up 1.5 percentage points from fiscal 2025 (13.0%). Over the past ten years it has ranged from −24.2% (fiscal 2015) to 16.4% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −19.7% and above the Healthcare sector median of −30.9%.

Return on assets, annual

Embed this chart

Annual newest first

Period Return on assets Change (points)
FY2025 13.0% 4.00
FY2024 9.04% (0.25)
FY2023 9.29% 2.68
FY2022 6.61% 1.91
FY2021 4.70% (11.74)
FY2020 16.4% 11.75
FY2019 4.69% 13.70
FY2018 −9.01% (1.33)
FY2017 −7.68% 11.20
FY2016 −18.9% 5.29

Against its own ten years

Low −24.2% High 16.4%
Ten-year median 4.70%
Current reading's percentile 91

Return on assets against peers

What Return on assets is

ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.

Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)

The full definition of Return on assets →

More on DXCM